Cooley advised Jiangsu Hengrui Pharmaceuticals, a leading global pharmaceutical company headquartered in China with a focus on research, development, manufacturing and commercialization of innovative and high-quality healthcare products, on its strategic collaboration and exclusive worldwide (excluding mainland China) license agreement with Merck KGaA, Darmstadt, Germany and global license agreement (excluding the Greater China region and Korea) with Elevar Therapeutics.
